Vernalis acquires Moxatag (amoxicillin extended-release) from Pragma Pharma to treat tonsillitis and/or pharyngitis
Vernalis announced that it has acquired the US rights to Moxatag (amoxicillin extended-release tablets) from Pragma Pharmaceuticals. Pragma acquired Moxatag from Shionogi in March 2014.
Moxatag is the first and only approved once-daily formulation of the antibiotic amoxicillin. Vernalis expect to re-launch the finished dose product by the end of 2015.
Approved by the FDA in 2008, Moxatag is a penicillin-class antibacterial indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and paediatric patients 12 years of age or older. It was approved based on a Phase III efficacy study and is protected by six Orange Book listed patents, the last of which expires in 2027. It has not been actively promoted since 2010.
Comment: The product offers patients a significant advantage in that treatment requires just one pill a day, while other amoxicillin-based tablets need to be taken two-three times daily for 10 days, depending on the severity of the infection.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins